Novus Biologicals launches new HIF Prolyl Hydroxylase Antibody

Novus Biologicals, a leading supplier of hypoxia-inducible factor (HIF) antibodies, recently launched a new HIF Prolyl Hydroxylase 3 antibody (catalog #: NBP1-22574).  HIF prolyl hydroxylase 3 is a prolyl hydroxylase that specifically modifies HIF1-alpha. Classic prolyl hydroxylases are found in the endoplasmic reticulum and modify collagen; whereas HIF is an intracellular protein and the HPH sites do not resemble those modifying collagen. HIF is a transcriptional complex that plays a critical role in oxygen homeostasis. HPH is an essential component of the pathway through which cells sense oxygen. In the presence of oxygen, HPHs convert specific prolyl residues in HIF1-alpha to hydroxyproline, leading to HIF1-alpha destruction. Low oxygen levels, sensed at the cellular level, cause the HIF conversion to be reduced so that HIF is stable and there is increased angiogenesis.

Novus' newly released mouse monoclonal anti- HIF Prolyl Hydroxylase 3 antibody (clone A1.10) was made to the full length human PHD3 protein purified from Sf9 insect cells.  It is protein G purified and was QC tested in Western blot on PHD3 overexpression lysate resulting in a clear band at 27kDa.

Researchers interested in HIF Prolyl Hydroxylase 3 antibodies can use Novus' bioinformatic tool, the Novus Explorer, to investigate relationships between HIF Prolyl Hydroxylase 3 and other genes, diseases and pathways.


 For more information on this newly released antibody or to inquire about product collaborations, please contact the Novus Product Development Team by calling 303-730-1950 or via e-mail at

Release Date: 
Monday, January 18, 2010 - 07:00